Bone marrow uptake of ferumoxytol: a preliminary study in healthy human subjects.
Bone marrow uptake of ferumoxytol: a preliminary study in healthy human subjects.
复制标题
菲鲁莫托的骨髓摄取：健康人类受试者的初步研究。
DOI：
10.1002/jmri.24320
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Arbini,ArnaldoA
中科院分区：
文献类型：
--
作者：
Storey,Pippa;Arbini,ArnaldoA
PurposeTo表征ferumoxytol，超小型超顺磁性氧化铁（USPIO）剂，在健康人类subjects.Materials和Methods 4名男性和2名绝经后女性，年龄在22至57岁的骨髓中的吸收和消除，前瞻性地包括在内。同时脂肪，水，和 使用三维多重梯度回波序列在1.5 T下对股骨近端进行标测。在基线成像后，以5 mg Fe/kg体重的剂量静脉内注射ferumoxytol（Feraheme/Rienso）。在给药后3天、1个月、3个月和5个月重复成像。 （）造血骨髓中的平均反应较低，脂肪骨髓中的平均反应较低，与巨噬细胞特异性摄取一致。然而，骨干的某些区域表现出大量的 尽管脂肪含量很高，但仍有增强作用。这表明脂肪转化后残留骨髓基质的持续存在，并可能反映骨干骨髓动态适应造血需求波动的能力。随访成像显示几乎完成 3个月内恢复。 增强特性支持了ferumoxytol在区分正常或细胞过多的骨髓与肿瘤、感染和炎症中的应用。在特定的患者人群中进行进一步的研究是必要的。Imaging 2014;39：1401-1410.©2013威利期刊公司.
PurposeTo characterize the uptake and elimination of ferumoxytol, an ultrasmall superparamagnetic iron oxide (USPIO) agent, in bone marrow of healthy human subjects.Materials and MethodsFour men and two postmenopausal women, aged 22 to 57 years, were prospectively included. Simultaneous fat, water, and mapping of the proximal femora was performed at 1.5 Tesla using a three‐dimensional multiple gradient echo sequence. After baseline imaging, ferumoxytol (Feraheme/Rienso) was injected intravenously at a dose of 5 mg Fe/kg body weight. Imaging was repeated at 3 days, 1 month, 3 months, and 5 months after administration.ResultsImaging at 3 days revealed large increases in ( ) in hematopoietic marrow and lower average responses in fatty marrow, consistent with macrophage‐specific uptake. However, certain regions of the diaphysis exhibited substantial enhancement despite having very high fat content. This suggests the persistence of residual marrow stroma following adipose conversion, and may reflect the ability of diaphyseal marrow to adapt dynamically to fluctuating demand for hematopoiesis. Follow‐up imaging demonstrated almost complete recovery within 3 months.ConclusionThe observed enhancement characteristics support applications for ferumoxytol in distinguishing normal or hypercellular marrow from neoplasms, infection and inflammation. Further studies are warranted in specific patient populations.J. Magn. Reson. Imaging 2014;39:1401–1410. ©2013 Wiley Periodicals, Inc.